InnoTherapy

Unprecedented Surgical Biomaterials with Adhesion Power. Learn more

Launch date

2010

Employees

2-10 people

Market cap

Enterprise valuation

CAD75m (Public information from Sep 2024)

Seongnam-si South Korea (HQ)

http://innotherapy.com

https://www.facebook.com/login.php https://www.linkedin.com/company/innotherapy-inc

Revenues, earnings & profits over time

KRW	2017	2018	2019	2020	2021	2022	2023
Revenues	203m	512m	693m	596m	507m	370m	1.3b
% growth	-	152 %	35 %	(14 %)	(15 %)	(27 %)	257 %
EBITDA	(2.2b)	(2.3b)	(3.5b)	(3.2b)	(3.9b)	(3.8b)	(3.2b)
% EBITDA margin	(1082 %)	(443 %)	(502 %)	(529 %)	(762 %)	(1040 %)	(243 %)
Profit	(3.0b)	(2.6b)	(4.0b)	(3.0b)	(5.0b)	(6.0b)	(5.0b)
% profit margin	(1484 %)	(503 %)	(576 %)	(511 %)	(992 %)	(1614 %)	(380 %)
EV / revenue	-	-	86.3x	137.4x	134.4x	149.6x	47.8x
EV / EBITDA	-	-	-17.2x	-25.9x	-17.6x	-14.4x	-19.6x
R&D budget	-	-	-	1.2b	1.4b	1.3b	1.2b
R&D % of revenue	-	-	-	208 %	281 %	362 %	93 %

Date	Investors	Amount	Round
Jan 2013*	DADAM Investment	N/A	-
Feb 2019	N/A	N/A	IPO
Total Funding		-

InnoTherapy specializes in developing innovative blood technology solutions, particularly in the area of hemostasis, which is the process of stopping bleeding. The company leverages protein-based advancements to create cutting-edge medical products. InnoTherapy serves healthcare providers and medical institutions, primarily operating in the Asian market. The business model includes research and development collaborations, licensing agreements, and strategic partnerships. Revenue is generated through product sales, licensing fees, and collaborative research funding. The company is committed to global marketing and overseas clinical study approvals to expand its market reach.

Keywords: hemostasis, blood technology, protein advancements, healthcare innovation, medical products, R&D collaborations, licensing, strategic partnerships, global marketing, clinical studies.